"10.1371_journal.pone.0059119","plos one","2013-03-21T00:00:00Z","Bruno Rivas-Santiago; Julio E Castañeda-Delgado; Cesar E Rivas Santiago; Matt Waldbrook; Irma González-Curiel; Juan C León–Contreras; Jose Antonio Enciso-Moreno; Victor del Villar; Jazmin Mendez-Ramos; Robert E W Hancock; Rogelio Hernandez-Pando","Medical Research Unit Zacatecas, Mexican Institute of Social Security-IMSS, Zacatecas, Mexico; Section of Experimental Pathology, National Institute of Medical Sciences and Nutrition Salvador Zubirán, Mexico City, Mexico; UMDNJ-School of Public Health, Department of Environmental and Occupational Health, Center for Global Public Health, Piscataway, New Jersey, United States of America; Department of Immunology, School of Medicine, Autonomous University of San Luis Potosi, San Luis Potosi, Mexico; Centre for Microbial Diseases and Immunity Research, University of British Columbia, Vancouver, British Columbia, Canada","Conceived and designed the experiments: BRS RHP REWH. Performed the experiments: BRS JECD CERS MW IGC JLC VV JMR. Analyzed the data: BRS JECD JAEM RHP MW REWH. Contributed reagents/materials/analysis tools: BRS RHP REWH. Wrote the paper: BRS RHP REWH.","Peptides IDR-1018, HH2 and 1002, discovered by Hancock and colleagues, have been filed for patent protection in multiple jurisdictions, assigned to UBC and licenced to Elanco (IDR-1018,HH2) for Animal Health applications and IDR-1018 is also under development as a potential therapeutic for hyperinflammation in Cystic Fibrosis with funding from Cystic Fibrosis Canadas Translational Initiative. Peptides 1002 and HH2 have also been developed as components of vaccine adjuvant formulations which have been licensed to Prepare with other licences pending. The peptide IDR-1018 has received Notice of allowance in the United States of America and New Zealand.","2013","03","Bruno Rivas-Santiago","BRS",11,TRUE,3,8,6,3,TRUE,TRUE,FALSE,0,NA,FALSE
